Application of drug repositioning strategy to TOFISOPAM

Current Medicinal Chemistry

Volumn 15, Issue 30, 2008, Pages 3196-3203

  Bernard, Philippe ^a   Dufresne Favetta, C ^b   Favetta, P ^b   Do, Q T ^a   Himbert, F ^a   Zubrzycki, S ^b   Scior, T ^a   Lugnier, C ^c  

^a Greenpharma SA   (France)

^b UNIVERSITÉ D'ORLÉANS   (France)

^c CNRS   (France)

Author keywords

Chiral purification; PDE4; Reverse docking; SELNERGY

Indexed keywords

CYCLIC AMP; PHOSPHODIESTERASE IV; TOFISOPAM; BENZODIAZEPINE DERIVATIVE;

CHEMICAL ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG DETERMINATION; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENANTIOMER; ENANTIOSELECTIVITY; ENZYME INHIBITION; MOLECULAR DOCKING; PRODUCTIVITY; RACEMIC MIXTURE; REVIEW; ARTICLE; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; CONFORMATION; DRUG ANTAGONISM; DRUG SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

BENZODIAZEPINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DRUG EVALUATION, PRECLINICAL; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 61549099680     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986708786848488     Document Type: Review

References (16)

1. Wermuth C.G.; Selective optimization of side activities: The SOSA approach. Drug Discov. Today, 2006, 11, 160-4.
2. Carley D.W. Drug repurposing: Identify, develop and commercialize new uses for existing or abandoned drugs. Part I. IDrugs, 2005, 8, 306-9.
3. Carley D.W. Drug repurposing: Identify, develop and commercialize new uses for existing or abandoned drugs. Part II. IDrugs, 2005, 8, 310-3.
4. Bernard, P. Phosphodiesterase-inhibiting compounds of the 2,3-benzodiazepine type. Patent WO2005113517; 2005.
5. Bourguignon J.J.; Lagouge Y.; Lugnier C. Compounds Inhibiting cyclic nucleotide phosphodiesterases, preparation and uses thereof. Patent WO02088096; 2002.
6. Do Q.T.; Renimel I.; Andre P.; Lugnier C.; Muller C.D.; Bernard P. Reverse pharmacognosy: Application of selnergy, a new tool for lead discovery. The example of epsilon-viniferin. Curr. Drug Discov. Technol., 2005, 2, 161-7.
7. Rarey M.; Kramer B.; Lengauer T.; Klebe G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol., 1996, 261, 470-89.
8. Vigers G.P.; Rizzi J.P. Multiple active site corrections for docking and virtual screening. J. Med. Chem., 2004, 47, 80-9
9. Lugnier C.; Schoeffter P.; Le Bec A.; Strouthou E.; Stoclet J.C. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol., 1986, 35, 1743-51.
10. Keravis T.M.; Wells J.N.; Hardman J.G. Cyclic nucleotide phosphodiesterase activities from pig coronary arteries. Lack of interconvertibility of major forms. Biochim. Biophys. Acta, 1980, 613, 116-29.
11. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol. Ther. 2006, 109, 366-98.
12. Visy J.; Simonyi M. The role of configuration and conformation in the binding of 2,3-benzodiazepines to human serum albumin. Chirality, 1989, 1, 271-5.
13. Zsila F.; Gergely A.; Horvath P.; Szasz G. Separation and identification of tofisopam stereoisomers by hyphenated HPLC-CD technique. J. Liq. Chrom. & Rel. Technol., 1999, 22, 713-19.
14. Tóth G.; Fogassy E.; Ács M.; Toke L.; Láng T. Racematspaltung von (F)-5-Ä thyl-1-(3,4-dimethoxyphenyl)-6,7-dimethoxy-4-methyl-5H-2, 3-benzodiazepin und anomales chiroptisches Verhalten der Enantiomeren J. Heterocyclic Chem., 1983, 20, 709-13.
15. Fitos I.; Visy J.; Simonyi M. Species-dependency in chiral-drug recognition of serum albumin studied by chromatographic methods. J. Biochem. Biophys. Methods, 2002, 54, 71-84.
16. Perrin S.R.; Galbraith K.B.; Ye N. Method for isolating (R)-tofisopam. Patent US 0254174 A1, 2004.